Literature DB >> 1571460

Hepatitis due to herpes simplex virus in marrow-transplant recipients.

J R Johnson1, S Egaas, C A Gleaves, R Hackman, R A Bowden.   

Abstract

Eight cases of hepatitis due to herpes simplex virus (HSV) (five "confirmed," three "possible") were identified among marrow-transplant recipients at the Fred Hutchinson Cancer Research Center between 1975 and 1988. The clinical and pathological characteristics of these patients are described and compared with published findings for non-marrow-transplant recipients with HSV hepatitis. Clinical syndromes in the marrow-transplant recipients ranged from fever associated with abdominal pain and elevations in serum aminotransferase levels to fulminant hepatitis. Evidence of hepatic infection appeared before day 20 following transplantation unless prophylaxis with acyclovir was given, in which case HSV hepatitis did not appear until after day 40. All patients died, although the one patient who was given early, empirical high-dose acyclovir therapy clearly improved with antiviral therapy and may have died of other causes. Involvement of multiple organs with HSV was found in three of four patients with confirmed HSV hepatitis who underwent autopsy. In all cases, reactivation of latent HSV was the presumed source of the HSV hepatitis. HSV hepatitis should be considered when HSV-seropositive recipients of marrow transplants develop abdominal pain, fever, and elevations in aminotransferase levels.

Entities:  

Mesh:

Year:  1992        PMID: 1571460     DOI: 10.1093/clinids/14.1.38

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Five cases of fulminant hepatitis due to herpes simplex virus in adults.

Authors:  Antonio D Pinna; Jorge Rakela; Anthony J Demetris; John J Fung
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Herpes Simplex Virus Infection Mimicking Bullous Disease in an Immunocompromised Patient.

Authors:  Anne L Y Lecluse; Carla A F M Bruijnzeel-Koomen
Journal:  Case Rep Dermatol       Date:  2010-06-15

Review 4.  Genital herpes: review of the epidemic and potential use of type-specific serology.

Authors:  R L Ashley; A Wald
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 5.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

6.  Genotypic Characterization of Herpes Simplex Virus Type 1 Isolates in Immunocompromised Patients in Rio de Janeiro, Brazil.

Authors:  Amanda Perse da Silva; Amanda de Oliveira Lopes; Yasmine Rangel Vieira; Adilson José de Almeida; Fernando Samuel Sion; Beatriz Grinsztejn; Sandra Wagner; Vanessa Salete de Paula
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

7.  Immune- and Nonimmune-Compartment-Specific Interferon Responses Are Critical Determinants of Herpes Simplex Virus-Induced Generalized Infections and Acute Liver Failure.

Authors:  Zachary M Parker; Tracy Jo Pasieka; George A Parker; David A Leib
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

8.  Clinical correlates of herpes simplex virus viremia among hospitalized adults.

Authors:  William R Berrington; Keith R Jerome; Linda Cook; Anna Wald; Lawrence Corey; Corey Casper
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

9.  Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007.

Authors:  Jen-Hsiang Shen; Kuan-Ying Arthur Huang; Chen Chao-Yu; Chih-Jung Chen; Tzou-Yien Lin; Yhu-Chering Huang
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.